A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00186433

Enrollment

Registered

2005-09-16

Start date

2001-11-30

Completion date

2013-06-30

Last updated

2015-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancers, Lip Cancer, Lip Neoplasms, Mouth Cancer, Throat Cancer

Brief summary

1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (NPC). 2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these tumors both in endemic and non-endemic areas. 3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for both endemic and non-endemic patient populations.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Having a new diagnosis of Nasopharyngeal carcinoma. * Being treated with either radiotherapy or chemoradiotherapy for this condition.

Exclusion criteria

* Age \<18 since NPC is a very rare condition in this age group and may have a different biological behavior * Patients who are unable to provide informed consents for themselves.

Design outcomes

Primary

Measure	Time frame	Description
Plasma Epstein-Bar Virus (EBV) DNA concentrations	every 6 months until end of study	measured by quantitative polymerase chain reaction (PCR)

Countries

United States

Outcome results